# US 2021/0228853 A1 · Drug delivery methods targeting the lymphatic system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228853 A1
- Document ID: US20210228853A1
- Status: Published application
- Kind: A1
- Application number: 15/733,817
- Filed: 2019-05-30
- Published: 2021-07-29
- Earliest claimed: 2018-05-31
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: RUSSELL FREDERICK ROSS
- Web page: https://patentgrep.com/patent/US20210228853A1

## CPC

- A61M 37/0015: {by using microneedles}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2818: {against CD28 or CD152}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein is a method for administering a therapeutic agent to multiple regions of the lymphatic system of a patient. The method generally includes placing two medical devices comprising a plurality of microneedles on the skin of the patient at two different locations proximate lymph vessels and/or lymph capillaries that drain into the right lymphatic duct and the thoracic duct; inserting the plurality of microneedles of medical devices into the patient to a depth whereby at least the epidermis is penetrated and administering via the microneedles of the medical devices a therapeutic agent into the lymphatic system of the patient. Disclosed herein also is a method for preventing or reducing cancer metastasis in a patient. Disclosed herein also is a method for treating an inflammatory medical condition in a patient.

## Claims

### Claim 1

A method for administering a therapeutic agent to the lymphatic system of a patient, the method comprising:
placing a first medical device comprising a plurality of microneedles on the skin of the patient at a first location proximate to a first position under the skin of the patient, wherein the first position is proximate to lymph vessels and/or lymph capillaries that drain into the right lymphatic duct, and wherein the microneedles of the first medical device have a surface comprising nanotopography;
placing a second medical device comprising a plurality of microneedles on the skin of the patient at a second location proximate to a second position under the skin of the patient, optionally wherein the first and second medical devices are the same device, wherein the second position is proximate to lymph vessels and/or lymph capillaries that drain into the thoracic duct, and wherein the microneedles of the second medical device have a surface comprising nanotopography;
inserting the plurality of microneedles of the first medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position;
inserting the plurality of microneedles of the second medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the second position; and
administering via the microneedles of the first medical device a first dose of the therapeutic agent into the first position; and administering via the microneedles of the second medical device a second dose of the therapeutic agent into a second position.

### Claim 2 (depends on 1)

The method according to claim 1, wherein administering the first dose and administering the second dose is simultaneous.

### Claim 3 (depends on 1, 2)

The method according to any one of claim 1 or 2, wherein administering the first dose and administering the second dose partially overlap in time.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein administering the first dose and administering the second dose is sequential.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1-4, wherein the first and second medical devices are different devices.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the first and second medical devices are the same device.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1-6, wherein administering the doses cumulatively provides a therapeutically effective amount of the therapeutic agent.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1-7, wherein the first location and the second location are on different limbs of the patient.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1-8, wherein the first location and the second location are each independently proximate to the hands or the feet of the patient.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1-9, wherein one of the first location or the second location is on the right arm or the right leg of the patient and the other location is on the left arm or the left leg of the patient.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1-10, wherein the method further comprises:
placing a third medical device comprising a plurality of microneedles on the skin of the patient at a third location proximate to a third position under the skin of the patient, wherein the third position is proximate to lymph vessels and/or lymph capillaries;
inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the third position; and
administering via the third medical device a third dose of said therapeutic agent; and
wherein the third location is different than the first location and the second location, and
the third position is different that the first position and the second position.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the first location, the second location and the third location are on different limbs of the patient.

### Claim 13 (depends on 11, 12)

The method according to claim 11 or 12,
wherein the first position, the second position and the third position are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes, and
wherein the draining lymph nodes are selected from the group of lymph nodes found in the hands, the feet, thighs (femoral lymph nodes), arms, legs, underarm (the axillary lymph nodes), the groin (the inguinal lymph nodes), the neck (the cervical lymph nodes), the chest (pectoral lymph nodes), the abdomen (the iliac lymph nodes), the popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, paraaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes.

### Claim 14 (depends on 11, 12, 13)

The method according to any of claims 11-13, wherein the method further comprises:
placing a fourth medical device comprising a plurality of microneedles on the skin of the patient at a fourth location proximate to a fourth position under the skin of the patient, wherein the fourth position is proximate to lymph vessels and/or lymph capillaries;
inserting the plurality of microneedles of the fourth medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the fourth position; and
administering via the fourth medical device a fourth dose of said therapeutic agent; and
wherein the first location, the second location, the third location, and the fourth location are on different limbs of the patient.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the first dose and the second dose are administered simultaneously, and the third dose and the fourth dose are administered simultaneously, and
a beginning time for administering the first dose and the second dose is different than a beginning time for administering the third dose and the fourth dose with a period of time between the beginning times for administrating the doses.

### Claim 16 (depends on 14, 15)

The method according to any of claim 14 or 15, wherein
the third position drains into the right lymphatic duct; and
the fourth position drains into the thoracic duct.

### Claim 17 (depends on 16)

The method of claim 16 wherein the first location and the third location on the skin of the patient are different from each other, and the first position and the third position are different from each other, and
the first position and the third position are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes.

### Claim 18 (depends on 17)

The method of claim 17, wherein the second location and the fourth location on the skin of the patient are different from each other, and the second portion and the fourth portion of the lymphatic system are different from each other, and
the second position and the fourth position are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1-18, wherein administering the first dose of the therapeutic agent and administering the second dose of the therapeutic agent partially overlap in time.

### Claim 20

A method for administering a therapeutic agent to the lymphatic system of a patient, the method comprising:
placing a first medical device comprising a plurality of microneedles on the skin of the patient at a first location proximate to a first position under the skin of the patient, wherein the first position is proximate to lymph vessels and/or lymph capillaries that drain into the right lymphatic duct, and wherein the microneedles of the first medical device have a surface comprising nanotopography;
placing a second medical device comprising a plurality of microneedles on the skin of the patient at a second location proximate to a second position under the skin of the patient, wherein the second position is proximate to lymph vessels and/or lymph capillaries that drain into the thoracic duct, and wherein the microneedles of the second medical device have a surface comprising nanotopography, optionally wherein the first and second medical devices are the same medical device;
inserting the plurality of microneedles of the first medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position;
inserting the plurality of microneedles of the second medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the second position;
administering via the microneedles of the first medical device a first dose of the therapeutic agent into the first position; and
administering via the microneedles of the second medical device a second dose of the therapeutic agent into the second position,
wherein a beginning time for administering the first dose and the second dose are different and separated by a period of time.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the period of time is at least 4, 6, 8, 10, 12, 16, 24, 36, 48 or 72 hours.

### Claim 22 (depends on 20, 21)

The method according to any one of claim 20 or 21, wherein the first dose, the second dose, or the first and second doses together constitute a therapeutically effective dose.

### Claim 23 (depends on 20, 21, 22)

The method according to any one of claims 20-22, wherein the first dose and the second dose are therapeutically effective doses.

### Claim 24 (depends on 20, 21, 22, 23)

The method according to claims 20-23, wherein the method further comprises:
placing a third medical device comprising a plurality of microneedles on the skin of the patient at a third location proximate to a third position under the skin of the patient, wherein the third position is proximate to lymph vessels and/or lymph capillaries, and wherein the microneedles of the third medical device have a surface comprising nanotopography;
inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the third position; and
administering via the microneedles of the third medical device a third dose of the therapeutic agent into the third position;
wherein the beginning time for administering the first dose, the second dose, and the third dose are each separated by a period of time; and
the first location, the second location, and the third location are located on different limbs of the patient.

### Claim 25 (depends on 20, 21, 22, 23)

The method according to claims 20-23, wherein the method further comprises:
placing a third medical device comprising a plurality of microneedles on the skin of the patient at a third location proximate to a third position under the skin of the patient, wherein the third position is proximate to lymph vessels and/or lymph capillaries, and wherein the microneedles of the third medical device have a surface comprising nanotopography;
inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the third position; and
administering via the microneedles of the third medical device a third dose of the therapeutic agent into the third position;
wherein the beginning time for administering the first dose, the second dose, and the effective dose are each separated by a period of time; and
wherein the first location and the third location are different and are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes.

### Claim 26 (depends on 24, 25)

The method according to any one of claim 24 or 25, wherein the first dose, the second dose, the third dose, or a combination of any two or more thereof constitute a therapeutically effective dose.

### Claim 27 (depends on 24, 25, 26)

The method according to any one of claims 24-26, wherein the first dose, the second dose, and the third dose are therapeutically effective doses.

### Claim 28 (depends on 24, 25, 26, 27)

The method according to any of claims 24-27, wherein the first position and the third position flow initially into different lymph nodes.

### Claim 29 (depends on 24, 25, 26, 27, 28)

The method according to any of claims 24-28, wherein the method further comprises:
placing a fourth medical device comprising a plurality of microneedles on the skin of the patient at a fourth location proximate to a fourth position under the skin of the patient, wherein the fourth position is proximate to lymph vessels and/or lymph capillaries, and wherein the microneedles of the fourth medical device have a surface comprising nanotopography;
inserting the plurality of microneedles of the fourth medical device into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the fourth position; and
administering via the microneedles of the fourth medical device a fourth therapeutically effective dose of the therapeutic agent into the fourth position; and
wherein the beginning time for administering the first dose, the second dose, the third dose, and the fourth dose are each separated by a period of time; and
wherein the lymph vessels and/or lymph capillaries of the third position drain into right lymphatic duct, and the lymph vessels and/or lymph capillaries of the fourth position drains into the thoracic duct,
wherein the first location and the third location are different and are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes, and
wherein the second location and the fourth location are different and selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain into different lymph nodes.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the first dose, the second dose, the third dose, the fourth dose, or a combination of any two or more thereof constitute a therapeutically effective dose.

### Claim 31 (depends on 29, 30)

The method according to claim 29 or 30, wherein the first dose, the second dose, the third dose, and the fourth dose are therapeutically effective doses.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1-31, wherein the first and second locations deliver to lymphatic capillaries and/or vessels that drain into different lymph nodes.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 1-32, wherein the lymph nodes are selected from the group of lymph nodes found in the hands, the feet, thighs (femoral lymph nodes), arms, legs, underarm (the axillary lymph nodes), the groin (the inguinal lymph nodes), the neck (the cervical lymph nodes), the chest (pectoral lymph nodes), the abdomen (the iliac lymph nodes), the popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, paraaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the first location is a first arm and the second location is selected from a leg or arm on the opposite of the body of the patient.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the therapeutic agent is an immune-suppressing agent.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the therapeutic agent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab/hyaluronidase human, dor a biosimilar or bioequivalent of any of the foregoing.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the therapeutic agent is an anti-CTLA-4 antibody.

### Claim 38

A method for preventing or reducing cancer metastasis in a patient, the method comprising:
locating at least one lymph node in the patient that intervenes in the lymphatic system between a solid cancer tumor and a draining duct;
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient located between the intervening lymph node and the solid cancer tumor, wherein the first position is proximate to lymph vessels and/or lymph capillaries in the patient's lymphatic system, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position; and
administering via the plurality of microneedles to the first position a therapeutically effective amount of an anti-CTLA-4 antibody that is effective for preventing or reducing metastasis of the solid cancer tumor.

### Claim 39

A method for preventing or reducing cancer metastasis in a patient, the method comprising:
locating a solid cancer tumor in the patient; locating at least one lymph node in the patient that intervenes in the lymphatic system between the solid cancer tumor and a draining duct;
placing a medical device that comprises a plurality of microneedles on the skin of the patient at a first location on the skin of the patient that is proximate to lymph capillaries and/or lymph vessels that flow into the intervening lymph node, wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the lymph capillaries and/or lymph vessels that flow into the intervening lymph node a therapeutically effective amount of an anti-CTLA-4 antibody that is effective in preventing or reducing cancer metastasis.

### Claim 40

A method of treating cancer in a patient, comprising:
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient, wherein the first position is proximate to lymph vessels and/or lymph capillaries in the patient's lymphatic system, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated and an end of at least one of the microneedles is proximate to the first position; and
administering via the plurality of microneedles to the first position an anti-CTLA-4 antibody, thereby treating the cancer.

### Claim 41 (depends on 38, 39, 40)

The method according to any one of claims 38-40, wherein the cancer comprises a tumor.

### Claim 42 (depends on 38, 39, 40, 41)

The method according to any one of claims 38-41, wherein the medical device is placed, relative to the tumor, distal to the draining duct.

### Claim 43 (depends on 38, 39, 40, 41, 42)

The method according to claim 38-42, wherein at least one lymph node in the patient intervenes in the lymphatic system between the tumor and a draining duct; and the first position is located between the intervening lymph node and the tumor.

### Claim 44 (depends on 38, 39, 40, 41, 42, 43)

The method according to any one of claims 38-43, wherein the medical device is placed at a location on the skin of the patient having lymphatic capillaries and/or vessels that flow directly into the intervening lymph node without first passing through any prior lymph node.

### Claim 45 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is a cancer of the head and neck, and the lymph nodes are selected from the group consisting of the jugular lymph nodes, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof.

### Claim 46 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is an oral cavity cancer, and the lymph nodes are selected from the group consisting of the jugular lymph node chain, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof.

### Claim 47 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is a cancer of the pharynx, and the lymph nodes are selected from the group consisting of the jugular lymph node chain, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof.

### Claim 48 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is a melanoma, and the lymph nodes are selected from the group consisting of axillary lymph nodes, inguinal lymph nodes, jugular lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof.

### Claim 49 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is breast cancer, and lymph nodes are selected from the group consisting of the axillary lymph nodes, the internal mammary lymph nodes, the supraclavicular lymph nodes and combinations thereof.

### Claim 50 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is prostate cancer, and the lymph nodes are selected from the group consisting of the lumbar lymph nodes, the inguinal lymph nodes, the peritoneal lymph nodes and combinations thereof.

### Claim 51 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38-44, wherein the cancer is in the genital system of the patient with the proviso that it is not ovarian cancer, and the lymph nodes are selected from the group consisting of the lumbar lymph nodes, the inguinal lymph nodes, the peritoneal lymph nodes and combinations thereof.

### Claim 52 (depends on 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method according to any one of claims 38-51, wherein the anti-CTLA-4 antibody is imilimumab, a biosimilar thereof, or a bioequivalent thereof.

### Claim 53

A method for treating an inflammatory medical condition in a patient, the method comprising:
locating at least one inflammatory locus in the patient, wherein the at least one inflammatory locus comprises lymph vessels, lymph capillaries, lymph nodes, lymph organs or any combination thereof;
locating a first position in the lymphatic system of the patient that is upstream of the inflammatory locus;
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to the first position, wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the first position a therapeutically effective amount of an immune-suppressing agent that is effective in treating the inflammatory medical condition.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the upstream position in the lymphatic system is a lymph node selected from the group consisting of lymph nodes found in the hands, the feet, thighs (femoral lymph nodes), arms, legs, underarm (the axillary lymph nodes), the groin (the inguinal lymph nodes), the neck (the cervical lymph nodes), the chest (pectoral lymph nodes), the abdomen (the iliac lymph nodes), the popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, paraaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof.

### Claim 55 (depends on 53, 54)

The method according to any one of claim 53 or 54, wherein the at least one inflammatory locus in the patient is a joint or a psoriatic lesion.

### Claim 56 (depends on 53, 54, 55)

The method according to any one of claims 53-55, wherein the at least one inflammatory locus in the patient is a at least one joint selected from the group consisting of an ankle joint, a knee joint, a hip joint, a shoulder joint, an elbow joint, a metacarpophalangeal joint of the hands, a metatarsophalangeal joint in a foot, a wrist joint, a joint in the neck, and combinations thereof.

### Claim 57 (depends on 53, 54, 55, 56)

The method according to any one of claims 53-56, wherein the at least one inflammatory locus in the patient is a psoriatic lesion.

### Claim 58 (depends on 53, 54, 55, 56, 57)

The method according to any one of claims 53-57, wherein the inflammatory medical condition is selected from the group consisting of Behcet's disease, sarcoidosis, rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and combinations thereof.

### Claim 59

A method for lowering the TNF-α level in a patient, the method comprising:
locating a first position in the lymphatic system of the patient;
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to the first position, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the first position a therapeutically effective amount of an immune-suppressing agent that is effective in lowering the TNF-α level in the patient.

### Claim 60 (depends on 59)

The method according to claim 59, wherein the first position is at least one lymph node of the patient.

### Claim 61

A method for treating an inflammatory medical condition in a patient, the method comprising:
locating at least one inflammatory locus in the patient comprising lymph nodes, lymph capillaries, lymph vessel, lymph organs or any combination thereof;
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient, wherein the first position is situated such that it comprises selected lymph capillaries and/or lymph vessels that deliver lymph directly into the lymphatic system in the inflammatory locus, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the selected lymph capillaries and/or lymph vessels of the patient a therapeutically effective amount of an immune-suppressing agent that is effective in treating the inflammatory medical condition.

### Claim 62

A method for treating an inflammatory medical condition in a patient, the method comprising:
placing a medical device comprising a plurality of microneedles on the skin of the patient proximate to a first position under the skin of the patient, wherein the first position is situated such that it comprises lymph capillaries and/or lymph vessels that deliver lymph directly into the lymphatic system, and wherein the microneedles have a surface comprising nanotopography;
inserting the plurality of microneedles into the patient to a depth whereby at least the epidermis is penetrated; and
administering via the plurality of microneedles to the lymph capillaries and/or lymph vessels of the patient an immune-suppressing agent, thereby treating the inflammatory medical condition.

### Claim 63 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method according to any one of claims 53-62, wherein the first position is situated such that it comprises selected lymph capillaries and/or lymph vessels that deliver lymph directly into the lymphatic system in an inflammatory locus in the patient comprising lymph nodes, lymph capillaries, lymph vessel, lymph organs or any combination thereof.

### Claim 64 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method according to any one of claims 53-63, wherein, relative to the inflammatory locus, the selected lymph capillaries and/or vessels are located distal to the heart of the patient.

### Claim 65 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method according to any one of claims 53-64, wherein the at least one inflammatory locus in the patient is a joint.

### Claim 66 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method according to any one of claims 53-65, wherein the at least one inflammatory locus in the patient is at least one joint selected from the group consisting of an ankle joint, a knee joint, a hip joint, a shoulder joint, an elbow joint, a metacarpophalangeal joint of the hands, a metatarsophalangeal joint in a foot, a wrist joint, a joint in the neck, and combinations thereof.

### Claim 67 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a knee, and the selected lymph capillaries and/or vessels flow into the popliteal lymph nodes.

### Claim 68 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a knee, and relative to the knee, the selected lymph capillaries and/or vessels are located distal to the heart.

### Claim 69 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is the neck, and the selected lymph capillaries and/or vessels flow into the cervical lymph nodes.

### Claim 70 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is the neck, and, relative to the neck, the selected lymph capillaries and/or vessels are located distal to the heart.

### Claim 71 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a shoulder, and the selected lymph capillaries and/or vessels flow into the pectoral lymph nodes, the superclavical lymph nodes, the axillary lymph nodes or any combination thereof.

### Claim 72 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a shoulder, and, relative to the shoulder, the selected lymph capillaries and/or vessels are located distal to the heart.

### Claim 73 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is an elbow, and the selected lymph capillaries and/or vessels flow into the epitrochlear lymph nodes and/or brachial lymph nodes.

### Claim 74 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is an elbow, and relative to the elbow, the selected lymph capillaries and/or vessels are located distal to the heart.

### Claim 75 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a hip, and the selected lymph capillaries and/or vessels flow into the inguinal lymph nodes and/or the pelvic lymph nodes.

### Claim 76 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a hip, and, relative to the hip, the selected lymph capillaries and/or vessels are located distal to the heart.

### Claim 77 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 53-66, wherein the inflammatory locus is a hip, and, relative to the hip, the selected lymph capillaries and/or vessels are located proximate to the heart.

### Claim 78 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method according to any one of claims 53-77, wherein the inflammatory medical condition is rheumatoid arthritis.

### Claim 79 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method according to any one of claims 53-78, wherein the inflammatory locus is a psoriatic lesion.

### Claim 80 (depends on 79)

The method according to claim 79, wherein the selected lymph capillaries share common lymph vessels and/or lymph capillaries immediately adjacent to and/or within the psoriatic lesion.

### Claim 81 (depends on 79, 80)

The method according to claim 79 or 80, wherein the medical device is placed at a location on the skin of the patient having lymph capillaries and/or vessels that flow directly into the lymph nodes within and/or closest to the psoriatic lesion.

### Claim 82 (depends on 81)

The method according to claim 81, wherein, relative to the inflammatory locus, the first medical device administers a first therapeutic agent to selected lymph capillaries and/or vessels distal to the heart, and
the method further comprises administering via a second medical device a second therapeutic agent, which is an immune-suppressing agent, to selected lymph capillaries and/or vessels proximate to the heart.

### Claim 83 (depends on 82)

The method according to claim 82, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or bioequivalent thereof administered to the first position and the second therapeutic agent are the same or different.

### Claim 84 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 53-83, wherein the immune-suppressing agent is a TNF-α inhibitor.

### Claim 85 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 53-83, wherein the immune-suppressing agent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab/hyaluronidase human, or a biosimilar or bioequivalent of any of the foregoing.

### Claim 86 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 53-83, wherein the immune-suppressing agent is an antibody that inhibits TNF-α or etanercept or a biosimilar or bioequivalent thereof.

### Claim 87 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 53-83, wherein the immune-suppressing agent is adalimumab or a biosimilar or bioequivalent thereof.

### Claim 88 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 53-83, wherein the immune-suppressing agent is etanercept or a biosimilar or bioequivalent thereof.

### Claim 89 (depends on 86)

The method according to claim 86, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or bioequivalent thereof is adalimumab or a biosimilar or bioequivalent thereof.

### Claim 90 (depends on 86)

The method according to claim 86, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or bioequivalent thereof is etanercept or a biosimilar or bioequivalent thereof.

### Claim 91 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method according to any one of claims 53-90, wherein the first medical device is placed at a location on the skin of the patient having lymph capillaries and/or vessels that flow directly into the lymph nodes within and/or closest to the inflammatory locus.

### Claim 92 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method according to any one of claims 53-91, wherein the selected lymph capillaries and/or vessels, relative to the inflammatory locus, are distal to the heart.

### Claim 93 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method according to any one of claims 53-92, wherein the selected lymph capillaries and/or vessels, relative to the inflammatory locus, are proximate to the heart.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method according to any one of claims 1-93, wherein the patient is a mammal.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method according to any one of claims 1-94, wherein the patient is a human.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method according to any one of claims 1-95, wherein the medical device is a Sofusa™ drug delivery platform.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method according to any one of claims 1-96, wherein the medical device comprises a fluid delivery apparatus,
wherein the fluid delivery apparatus comprises:
a fluid distribution assembly wherein a cap assembly is coupled to a cartridge assembly, and the cartridge assembly is slidably coupled to a plenum assembly, and a mechanical controller assembly is slidably coupled to the cartridge assembly;
a collet assembly constituting the housing of the fluid delivery apparatus and being slidably coupled to the fluid distribution assembly; and
a plurality of microneedles fluidically connected with the fluid distribution assembly having a surface comprising nanotopography, the plurality of microneedles being capable of penetrating the stratum corneum of the skin of a patient and controllably delivering the therapeutic agent, the anti-CTLA-4 antibody, or the immune-suppressing agent to a depth below the surface of the skin.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method according to any one of claims 1-97, wherein the medical device delivers the therapeutic agent or the anti-CTLA-4 antibody or the immune-suppressing agent to a depth below the surface of the skin of from about 50 μm to about 4000 μm, from about 250 μm to about 2000 μm, or from about 350 μm to about 1000 μm.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method according to any one of claims 1-98, wherein each of the microneedles in the medical device has a length between about 200 to about 800 μm, between about 250 to about 750 μm, or between about 300 to about 600 μm.
